Skip to content
Inciteful Med

The Diagnostic Checklist: Understanding Your Testing

Last updated:

Scleroderma is diagnosed using the 2013 ACR/EULAR criteria, where a score of 9 or higher indicates systemic sclerosis. A complete diagnostic workup requires baseline tests to check for organ involvement, including chest HRCT scans for lung scarring, lung function tests, skin thickness scoring (mRSS), and specific autoantibody panels.

Key Takeaways

  • • A scleroderma diagnosis is officially classified using the 2013 ACR/EULAR criteria, requiring a score of 9 or higher.
  • • High-Resolution Computed Tomography (HRCT) is the gold standard test for detecting early lung scarring.
  • • The Modified Rodnan Skin Score (mRSS) physically evaluates and tracks skin thickening across 17 different areas of the body.
  • • Nailfold capillaroscopy is a non-invasive microscopic exam that checks for microscopic blood vessel damage at the base of your fingernails.
  • • A complete baseline workup must include a full autoantibody panel, HRCT, lung function tests, an echocardiogram, and skin scoring.

Diagnosing scleroderma is like putting together a complex puzzle. Because the disease is so rare and variable, doctors use a specific, weighted scoring system and a set of “gold standard” baseline tests to determine exactly how the disease is behaving in your body [1][2].

The Diagnostic “Score”: 2013 ACR/EULAR Criteria

To be officially classified with Systemic Sclerosis (SSc), doctors use a point-based system. Generally, if your symptoms add up to a score of 9 or higher, you meet the criteria for diagnosis [3][4]. Key items that contribute points include:

  • Skin thickening on the fingers (this is the most heavily weighted item) [5].
  • Fingertip lesions, such as small pits or ulcers [5].
  • Telangiectasia (tiny, visible red blood vessels on the skin) [5].
  • Abnormal nailfold capillaries (seen under a microscope) [5].
  • Raynaud’s phenomenon (fingers changing color in the cold) [3].
  • Specific autoantibodies (like Anti-Scl-70 or Anticentromere) [5].

The Three Pillars of Your Baseline Workup

Once a diagnosis is suspected, you must have “baseline” tests. These serve as a snapshot of your health today so your care team can detect even tiny changes in the future [1].

1. The Lungs: HRCT and PFTs

Lung involvement is the most serious complication, but it can be “silent” early on.

  • High-Resolution Computed Tomography (HRCT): This is the gold standard for detecting lung scarring (fibrosis). It can find early changes that a standard X-ray or even breathing tests might miss [6][7].
  • Pulmonary Function Tests (PFTs): These measure how much air your lungs can hold and how well they move oxygen into your blood. Doctors look specifically at your FVC (Forced Vital Capacity) and DLco [8][9].

2. The Skin: Modified Rodnan Skin Score (mRSS)

The mRSS is the gold standard for measuring skin thickness. A doctor will physically pinch the skin at 17 different sites on your body (including your fingers, arms, chest, and legs) and score each area from 0 (normal) to 3 (severe thickening). The maximum score is 51 [10][11].

3. The Vessels: Nailfold Capillaroscopy (NFC)

This is a non-invasive test where a doctor puts a drop of oil on the base of your fingernail and looks at the tiny blood vessels (capillaries) through a specialized microscope [12]. They look for:

  • Giant capillaries: Usually the first sign of the disease [13].
  • Hemorrhages: Tiny bleeds that show vessel damage [13].
  • Avascular areas: Areas where blood vessels have “dropped out” or disappeared [13].

Your Completeness Checklist

Ensure your medical file contains these “must-have” baseline results to correctly stage your disease:

  1. [ ] Full Autoantibody Panel: Specifically looking for Anti-Scl-70, Anticentromere, and Anti-RNA Polymerase III [14].
  2. [ ] Baseline HRCT of the Chest: To screen for Interstitial Lung Disease [6].
  3. [ ] Baseline PFTs: To measure lung volume and oxygen exchange [9].
  4. [ ] Baseline Echocardiogram: To screen for heart strain or high pressure in the lung’s blood vessels (PAH) [15].
  5. [ ] Initial mRSS (Skin Score): A 17-point physical exam recorded in your chart [16].
  6. [ ] Home Blood Pressure Monitoring: Essential for early detection of Scleroderma Renal Crisis, especially if you have the diffuse subtype or Anti-RNA Polymerase III antibodies [17][18].

Frequently Asked Questions

What score is needed to be diagnosed with scleroderma?
Doctors use the 2013 ACR/EULAR criteria, which is a point-based system. Generally, if your symptoms, physical exam findings, and lab test results add up to a score of 9 or higher, you meet the official criteria for a systemic sclerosis diagnosis.
What is the Modified Rodnan Skin Score (mRSS)?
The mRSS is a physical exam used to measure skin thickness. A doctor will gently pinch your skin at 17 different sites on your body and score each area from 0 to 3 to determine the severity and extent of your skin involvement.
Why do I need a chest HRCT scan for scleroderma?
A High-Resolution Computed Tomography (HRCT) scan is the gold standard for detecting early lung scarring, known as pulmonary fibrosis. It is essential because it can identify microscopic lung changes that standard X-rays or basic breathing tests might miss.
What does a nailfold capillaroscopy look for?
This non-invasive test uses a specialized microscope to examine the tiny blood vessels at the base of your fingernail. Doctors look for abnormal giant capillaries, tiny bleeds, or areas where blood vessels have disappeared to assess vascular damage.
Which autoantibodies are tested for during a scleroderma workup?
A complete baseline blood panel for scleroderma looks for specific markers that help identify your disease subtype. The three primary autoantibodies tested are Anti-Scl-70, Anticentromere, and Anti-RNA Polymerase III.

Questions for Your Doctor

  • • What was my total score on the 2013 ACR/EULAR criteria, and which items contributed to that score?
  • • Is my nailfold capillaroscopy pattern classified as 'early,' 'active,' or 'late,' and what does that mean for my risk of lung or kidney issues?
  • • What is my baseline Modified Rodnan Skin Score (mRSS), and which of the 17 sites showed the most thickening?
  • • Based on my autoantibody profile (like Anti-RNA Polymerase III), do I need to check my blood pressure daily or twice daily?
  • • Did my baseline HRCT show any signs of 'occult' fibrosis (scarring) that wasn't picked up by my breathing tests?

Questions for You

  • • Have you noticed any tiny red spots (telangiectasias) on your face, lips, or hands? (These are a key diagnostic marker).
  • • Do you have a reliable blood pressure cuff at home, and do you know your 'normal' baseline reading?
  • • Are you experiencing any 'fingertip pits' or small, painful sores on your fingers that are slow to heal?
  • • When was the last time a doctor performed a physical exam to 'pinch' the skin on your arms, legs, and trunk?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients.

    Ruaro B, Baratella E, Confalonieri P, et al.

    Diagnostics (Basel, Switzerland) 2021; (11(11)) doi:10.3390/diagnostics11111960.

    PMID: 34829307
  2. 2

    Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort.

    Sáez-Comet L, Simeón-Aznar CP, Pérez-Conesa M, et al.

    The Journal of rheumatology 2015; (42(12)):2327-31 doi:10.3899/jrheum.150144.

    PMID: 26472418
  3. 3

    Validation of the ACR/EULAR classification criteria for systemic sclerosis in patients with early scleroderma.

    Araújo FC, Camargo CZ, Kayser C

    Rheumatology international 2017; (37(11)):1825-1833 doi:10.1007/s00296-017-3787-1.

    PMID: 28819792
  4. 4

    Validation of the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for systemic sclerosis in patients from a capillaroscopy clinic.

    Melchor S, Joven BE, Andreu JL, et al.

    Seminars in arthritis and rheumatism 2016; (46(3)):350-355 doi:10.1016/j.semarthrit.2016.05.007.

    PMID: 27373498
  5. 5

    New Classification Criteria for Systemic Sclerosis (Scleroderma).

    Pope JE, Johnson SR

    Rheumatic diseases clinics of North America 2015; (41(3)):383-98.

    PMID: 26210125
  6. 6

    The Impact of Progressive Pulmonary Fibrosis in Systemic Sclerosis-Associated Interstitial Lung Disease.

    Martín-López M, Carreira PE

    Journal of clinical medicine 2023; (12(20)) doi:10.3390/jcm12206680.

    PMID: 37892818
  7. 7

    Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis.

    Bernstein EJ, Jaafar S, Assassi S, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2020; (72(11)):1892-1896 doi:10.1002/art.41415.

    PMID: 32583956
  8. 8

    Systemic sclerosis-associated interstitial lung disease: How to manage in 2024?

    Bautista-Sanchez R, Khanna D

    Rheumatology and immunology research 2024; (5(3)):157-165 doi:10.2478/rir-2024-0022.

    PMID: 39439972
  9. 9

    Systemic sclerosis associated interstitial lung disease: a survey of current practices in France.

    Nicolas A, Leroy S, Mouthon L, et al.

    Therapeutic advances in musculoskeletal disease 2023; (15()):1759720X231159712 doi:10.1177/1759720X231159712.

    PMID: 37187855
  10. 10

    Systemic sclerosis (scleroderma): remaining challenges.

    Connolly MK

    Annals of translational medicine 2021; (9(5)):438 doi:10.21037/atm-20-5449.

    PMID: 33842659
  11. 11

    Translational optical coherence elastography for assessment of systemic sclerosis.

    Liu CH, Assassi S, Theodore S, et al.

    Journal of biophotonics 2019; (12(12)):e201900236 doi:10.1002/jbio.201900236.

    PMID: 31343837
  12. 12

    Position article and guidelines 2018 recommendations of the Brazilian Society of Rheumatology for the indication, interpretation and performance of nailfold capillaroscopy.

    Kayser C, Bredemeier M, Caleiro MT, et al.

    Advances in rheumatology (London, England) 2019; (59(1)):5 doi:10.1186/s42358-018-0046-4.

    PMID: 30670098
  13. 13

    Nailfold capillaroscopy in systemic diseases: short overview for internal medicine.

    Dima A, Berza I, Popescu DN, Parvu MI

    Romanian journal of internal medicine = Revue roumaine de medecine interne 2021; (59(3)):201-217 doi:10.2478/rjim-2021-0007.

    PMID: 33600677
  14. 14

    Kidney Transplantation in a Patient with Scleroderma.

    Bear L, Agmon Levine N, Ghinea R, et al.

    The Israel Medical Association journal : IMAJ 2024; (26(9)):593-595.

    PMID: 39397508
  15. 15

    The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients.

    Ruaro B, Confalonieri M, Salton F, et al.

    Pharmaceuticals (Basel, Switzerland) 2021; (14(5)) doi:10.3390/ph14050403.

    PMID: 33922710
  16. 16

    Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma.

    Showalter K, Merkel PA, Khanna D, Gordon JK

    Journal of scleroderma and related disorders 2020; (5(3)):167-171 doi:10.1177/2397198320921044.

    PMID: 35382518
  17. 17

    Renal Involvement in Systemic Sclerosis: An Update.

    Chrabaszcz M, Małyszko J, Sikora M, et al.

    Kidney & blood pressure research 2020; (45(4)):532-548 doi:10.1159/000507886.

    PMID: 32521536
  18. 18

    [Renal Involvement in Connective Tissue Diseases].

    Weiner SM

    Deutsche medizinische Wochenschrift (1946) 2018; (143(2)):89-100 doi:10.1055/s-0043-106563.

    PMID: 29359289

This page explains scleroderma diagnostic criteria and testing for educational purposes. Your rheumatologist and specialist care team are the best sources for interpreting your specific test scores and planning your care.

Stay up to date

Get notified when new research about Scleroderma is published.

No spam. Unsubscribe anytime.